Printer Friendly

Adlai Nortye signs EP4 antagonist global licensing agreement with Eisai.

M2 EQUITYBITES-January 22, 2018-Adlai Nortye signs EP4 antagonist global licensing agreement with Eisai


Biopharmaceutical company Adlai Nortye Biopharma Co Ltd (NEEQ:870946) revealed on Friday the launch of the E7046 global licensing agreement with Eisai Co Ltd, a global pharmaceutical company, in the development of the former's oncology pipeline.

This agreement provides Adlai Nortye wiith the exclusive worldwide research, development, manufacture and commercialisation rights to E7046, excluding Japan and part of Asia other than Mainland China.

According to the company, E7046 is an investigational, oral EP4 antagonist (potentially first in class) with high activity and high selectivity.

Based on preliminary results, E7046 is well tolerated in patients with solid tumours. A Phase 1b combination study with radiotherapy and chemoradiotherapy is ongoing, concluded the company.

((Comments on this story may be sent to

COPYRIGHT 2018 Normans Media Ltd.
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2018 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:M2 EquityBites (EQB)
Date:Jan 22, 2018
Previous Article:Integrated Ventures announce acquisition of mining rigs and real estate worth USD650,000.
Next Article:Pure Multi-family declares distribution of USD0.03125 per unit for January 2018.

Terms of use | Privacy policy | Copyright © 2019 Farlex, Inc. | Feedback | For webmasters